A detailed history of Pax Financial Group, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Pax Financial Group, LLC holds 4,478 shares of NBIX stock, worth $648,683. This represents 0.13% of its overall portfolio holdings.

Number of Shares
4,478
Previous 5,421 17.4%
Holding current value
$648,683
Previous $681,000 7.78%
% of portfolio
0.13%
Previous 0.14%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 04, 2025

SELL
$123.98 - $146.67 $116,913 - $138,309
-943 Reduced 17.4%
4,478 $628,000
Q2 2025

Aug 11, 2025

SELL
$87.54 - $128.18 $220,338 - $322,629
-2,517 Reduced 31.71%
5,421 $681,000
Q1 2025

May 02, 2025

BUY
$107.22 - $153.29 $1,179 - $1,686
11 Added 0.14%
7,938 $877,000
Q4 2024

Feb 12, 2025

SELL
$111.62 - $139.44 $31,365 - $39,182
-281 Reduced 3.42%
7,927 $1.08 Million
Q3 2024

Nov 13, 2024

SELL
$114.58 - $153.15 $69,320 - $92,655
-605 Reduced 6.86%
8,208 $944,000
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $148,395 - $162,377
-1,134 Reduced 11.4%
8,813 $1.21 Million
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $56,332 - $62,095
-432 Reduced 4.16%
9,947 $1.37 Million
Q4 2023

Feb 12, 2024

SELL
$106.07 - $132.76 $127,496 - $159,577
-1,202 Reduced 10.38%
10,379 $1.37 Million
Q3 2023

Nov 13, 2023

SELL
$94.02 - $117.1 $553,871 - $689,836
-5,891 Reduced 33.72%
11,581 $1.3 Million
Q2 2023

Jul 18, 2023

BUY
$89.53 - $104.87 $108,958 - $127,626
1,217 Added 7.49%
17,472 $1.65 Million
Q1 2023

May 11, 2023

BUY
$94.11 - $123.02 $1.53 Million - $2 Million
16,255 New
16,255 $1.65 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Pax Financial Group, LLC Portfolio

Follow Pax Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pax Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pax Financial Group, LLC with notifications on news.